Cargando…

Implementing a clinical pharmacy service in hematology

OBJECTIVE: To implement a clinical pharmacy service focused on the comprehensive review of antineoplastic drugs used in therapy of hematological diseases. METHODS: An interventional study was conducted in a Brazilian tertiary teaching hospital in two different periods, with and without a clinical ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Farias, Tatiane Fernandes, Aguiar, Karina da Silva, Rotta, Inajara, Belletti, Klezia Morais da Silva, Carlotto, Juliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234751/
https://www.ncbi.nlm.nih.gov/pubmed/27759828
http://dx.doi.org/10.1590/S1679-45082016AO3667
_version_ 1782495043504832512
author Farias, Tatiane Fernandes
Aguiar, Karina da Silva
Rotta, Inajara
Belletti, Klezia Morais da Silva
Carlotto, Juliane
author_facet Farias, Tatiane Fernandes
Aguiar, Karina da Silva
Rotta, Inajara
Belletti, Klezia Morais da Silva
Carlotto, Juliane
author_sort Farias, Tatiane Fernandes
collection PubMed
description OBJECTIVE: To implement a clinical pharmacy service focused on the comprehensive review of antineoplastic drugs used in therapy of hematological diseases. METHODS: An interventional study was conducted in a Brazilian tertiary teaching hospital in two different periods, with and without a clinical pharmacy service, respectively. This service consisted of an antineoplastic prescription validation (analysis of patients' characteristics, laboratory tests, compliance with the therapeutic protocol and with pharmacotechnical parameters). When problems were detected, the pharmacist intervened with the physician or another health professional responsible for the patient. Inpatients and outpatients with hematological diseases were included. RESULTS: We found an increased detection of drug-related problem by 106.5% after implementing the service. Comparing the two periods, an increase in patients' age (26.7 years versus 17.6 years), a predominance of outpatients (54% versus 38%), and an increase in multiple myeloma (13% versus 4%) and non-Hodgkin lymphoma (16% versus 3%) was noted. The most commonly found problems were related to dose (33% versus 25%) and cycle day (14% versus 30%). With regard to clinical impact, the majority had a significant impact (71% versus 58%), and in one patient from the second period could have been fatal. The main pharmaceutical interventions were dose adjustment (35% versus 25%) and drug withdrawal (33% versus 40%). CONCLUSION: The pharmacy service contributed to increase the detection and resolution of drug-related problems, and it was an effective method to promote the safe and rational use of antineoplastic drugs.
format Online
Article
Text
id pubmed-5234751
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Instituto Israelita de Ensino e Pesquisa Albert Einstein
record_format MEDLINE/PubMed
spelling pubmed-52347512017-02-03 Implementing a clinical pharmacy service in hematology Farias, Tatiane Fernandes Aguiar, Karina da Silva Rotta, Inajara Belletti, Klezia Morais da Silva Carlotto, Juliane Einstein (Sao Paulo) Original Article OBJECTIVE: To implement a clinical pharmacy service focused on the comprehensive review of antineoplastic drugs used in therapy of hematological diseases. METHODS: An interventional study was conducted in a Brazilian tertiary teaching hospital in two different periods, with and without a clinical pharmacy service, respectively. This service consisted of an antineoplastic prescription validation (analysis of patients' characteristics, laboratory tests, compliance with the therapeutic protocol and with pharmacotechnical parameters). When problems were detected, the pharmacist intervened with the physician or another health professional responsible for the patient. Inpatients and outpatients with hematological diseases were included. RESULTS: We found an increased detection of drug-related problem by 106.5% after implementing the service. Comparing the two periods, an increase in patients' age (26.7 years versus 17.6 years), a predominance of outpatients (54% versus 38%), and an increase in multiple myeloma (13% versus 4%) and non-Hodgkin lymphoma (16% versus 3%) was noted. The most commonly found problems were related to dose (33% versus 25%) and cycle day (14% versus 30%). With regard to clinical impact, the majority had a significant impact (71% versus 58%), and in one patient from the second period could have been fatal. The main pharmaceutical interventions were dose adjustment (35% versus 25%) and drug withdrawal (33% versus 40%). CONCLUSION: The pharmacy service contributed to increase the detection and resolution of drug-related problems, and it was an effective method to promote the safe and rational use of antineoplastic drugs. Instituto Israelita de Ensino e Pesquisa Albert Einstein 2016 /pmc/articles/PMC5234751/ /pubmed/27759828 http://dx.doi.org/10.1590/S1679-45082016AO3667 Text en http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Farias, Tatiane Fernandes
Aguiar, Karina da Silva
Rotta, Inajara
Belletti, Klezia Morais da Silva
Carlotto, Juliane
Implementing a clinical pharmacy service in hematology
title Implementing a clinical pharmacy service in hematology
title_full Implementing a clinical pharmacy service in hematology
title_fullStr Implementing a clinical pharmacy service in hematology
title_full_unstemmed Implementing a clinical pharmacy service in hematology
title_short Implementing a clinical pharmacy service in hematology
title_sort implementing a clinical pharmacy service in hematology
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5234751/
https://www.ncbi.nlm.nih.gov/pubmed/27759828
http://dx.doi.org/10.1590/S1679-45082016AO3667
work_keys_str_mv AT fariastatianefernandes implementingaclinicalpharmacyserviceinhematology
AT aguiarkarinadasilva implementingaclinicalpharmacyserviceinhematology
AT rottainajara implementingaclinicalpharmacyserviceinhematology
AT bellettikleziamoraisdasilva implementingaclinicalpharmacyserviceinhematology
AT carlottojuliane implementingaclinicalpharmacyserviceinhematology